Novavax AI approach to COVID-influenza vaccine design pays off

18 May 2023

US biotech Novavax’ (Nasdaq: NVAX) COVID-influenza combination (CIC) vaccine reflects a wider industry trend for increased usage of artificial intelligence (AI) in clinical trial design, says data and analytics company GlobalData.

Novavax has recently announced top-line results from a Phase II trial for its CIC vaccine. The data indicates that the vaccine candidate is safe, well tolerated, and exhibits a strong immune response comparable to that of both influenza vaccines Fluad and Fluzone HD, as well as Novavax’s COVID-19 vaccineNVX-CoV2373.

Stephanie Kurdach, infectious disease analyst at GlobalData, comments: “Novavax’ novel AI approach, which informed dose selection of the CIC vaccine candidate, is paying off. With Phase III trials set to begin later this year, Novavax has a good chance to bring the first combined COVID-Influenza vaccine to market.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK